Division of Gynecologic Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Uterine Cervical Neoplasms 85%
3. Hysterectomy 77%
4. Ovarian Neoplasms 73%
5. Endometrial Neoplasms 68%
6. Endometrioid Carcinoma 68%
7. Vulva 65%
8. Radioimmunotherapy 58%
9. Oncogene Proteins 52%
10. Pandemics 44%
11. liposomal doxorubicin 44%
12. Recurrence 40%
13. Carcinoma 36%
14. Rhenium-188 32%
15. Malignant Mixed Tumor 31%
16. Survival 30%
17. Surgical Oncology 28%
18. Therapeutics 27%
19. Endometrial Hyperplasia 27%
20. Ovary 24%
21. Neoplasm Metastasis 23%
22. Adenocarcinoma 22%
23. Glutathione Peroxidase 21%
24. Quality Improvement 20%
25. Wolffian tumor 20%
26. Squamous Cell Carcinoma 19%
27. benzyloxycarbonylleucyl-leucyl-leucine aldehyde 19%
28. Transcriptome 19%
29. Antibodies 19%
30. Lutetium-177 18%
31. C1P5 monoclonal antibody 18%
32. Papanicolaou Test 17%
33. Single Nucleotide Polymorphism 17%
34. Cod Liver Oil 17%
35. Vaginal Hysterectomy 17%
36. AIDS-related Kaposi sarcoma 17%
37. Ascites 17%
38. Genes 16%
39. Groin 16%
40. Human papillomavirus 16 16%
41. Robotics 16%
42. Electrosurgery 15%
43. Peutz-Jeghers Syndrome 15%
44. Gestational Trophoblastic Disease 14%
45. Fertility 14%
46. Monoclonal Antibodies 14%
47. Clonal Evolution 14%
48. Neoplasm Antibodies 14%
49. Molecular Targeted Therapy 14%
50. Proteasome Inhibitors 14%
51. Histology 14%
52. Conservative Treatment 14%
53. Antioxidants 13%
54. Pemetrexed 13%
55. Surgeons 13%
56. Cytoreduction Surgical Procedures 13%
57. Progression-Free Survival 13%
58. Cardiotoxicity 12%
59. Papillomaviridae 12%
60. Vagina 12%
61. Epidural Analgesia 12%
62. Abdominal Wall 12%
63. Paclitaxel 12%
64. Genistein 12%
65. Granulosa Cells 12%
66. Pathologists 12%
67. Intestinal Obstruction 12%
68. Drug Therapy 12%
69. Laparoscopy 12%
70. Ovarian Epithelial Carcinoma 12%
71. Growth 12%
72. Amenorrhea 11%
73. Bevacizumab 11%
74. Length of Stay 11%
75. Oxidation-Reduction 11%
76. Cisplatin 11%
77. Inhibins 11%
78. Lymph Nodes 11%
79. Medicine 11%
80. Endometriosis 11%
81. Transforming Growth Factors 11%
82. Genome-Wide Association Study 10%
83. Cell Biology 10%
84. Endometrium 10%
85. Microarray Analysis 10%
86. Head and Neck Neoplasms 10%
87. Radiotherapy 10%
88. Referral and Consultation 10%
89. Multiple Myeloma 10%
90. Treatment Failure 10%
91. Hispanic Americans 10%
92. Crohn Disease 10%
93. Sarcoma 9%
94. Disease-Free Survival 9%
95. Adenoma 9%
96. Disease Progression 9%
97. Teaching Hospitals 9%
98. Fingers 9%